Myrobalan Therapeutics is a biotechnology company developing oral neurorestorative therapies for individuals with CNS diseases.
Myrobalan Therapeutics has raised $850K in total funding. The most recent round was Grant. The last funding was announced in March 2025.
Myrobalan Therapeutics's investors include 3E Bioventures, National Multiple Sclerosis Society (NMSS), Cowin Venture, The ALS Association, AB Magnitude Ventures Group.
Myrobalan Therapeutics is headquartered in Medford, United States.
Myrobalan Therapeutics is a biotechnology company developing oral neurorestorative therapies for individuals with CNS diseases.
Myrobalan Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Myrobalan Therapeutics — Funding & Investors." VCBacked, March 13, 2025, https://www.vcbacked.co/company/myrobalan-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Myrobalan Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/myrobalan-therapeutics
{{cite web |title=Myrobalan Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/myrobalan-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated